NEW YORK ( TheStreet) -- CHANGE IN RATINGSArcher-Daniels Midland was upgraded at J.P. Morgan to neutral from underweight. Company should benefit from lower corn prices, J.P. Morgan said. AIMCO ( AIV) was downgraded at UBS to neutral from buy and given a $32 price target. 2013 same-store sales are unlikely to be raised, and the portfolio is exposed to rising cap rates, UBS said. Advanced Micro Devices ( AMD) was downgraded at Credit Suisse to underperform from neutral. $3 price target. Profitability continues to be challenging, Credit Suisse said. Advanced Micro Devices was downgraded at Morgan Stanley to underweight. $2.50 price target. Console margins appear to be lower than previously thought, Morgan Stanley said.
AthenaHealth ( ATHN) was downgraded at Lazard Capital Markets to neutral from buy. Valuation call, as the stock has been strong of late, Lazard Capital Markets said. Cepheid ( CPHD) was upgraded at Piper Jaffray to overweight from neutral. Valuation call, based on a $43 price target, Piper Jaffray said. CYS Investments ( CYS) was downgraded to sell at TheStreet Ratings. Fairchild Semiconductor ( FCS) was downgraded at FBR Capital Markets to market perform from outperform. $14 price target. Company lowered its guidance, FBR Capital Markets said.
Family Dollar ( FDO) was initiated with a market perform rating at FBR Capital Markets. $64 price target. Consensus estimates appear to be aggressive, FBR Capital Markets said. Piper Jaffray ( PJC) was downgraded to hold at TheStreet Ratings. ICU Medical ( ICUI) was downgraded at Piper Jaffray to neutral from overweight. $71 price target. Company missed expectations this quarter, but remains a possible takeover target, Piper Jaffray said. International Game ( IGT) was downgraded at Credit Suisse to underperform from neutral. $16 price target. Core business remains challenged, Credit Suisse said. Intuitive Surgical ( ISRG) was downgraded at JMP Securities to underperform from market perform. $275 price target. Company has received an FDA warning letter and will see no additional reimbursements in Japan next year, JMP Securities said.